September 17, 2025
Innovative Trends in Pediatric Obstructive Sleep Apnea: Vivos Therapeutics Landmark Clinical Trial Results Pediatric obstructive sleep apnea (OSA) presents significant challenges, both to clinical management and overall pediatric health. In recent years, the prevalence of this condition has garnered increased attention, prompting a concerted effort within the medical community to explore and validate effective treatments. At the forefront of this endeavor is Vivos Therapeutics Inc., a pioneering company dedicated to developing novel therapeutic solutions for sleep disorders. Vivos Therapeutics Clinical Trial BreakthroughIn a landmark clinical trial, Vivos Therapeutics announced promising results that coul...
September 18, 2024
In a landmark moment for pediatric healthcare, Vivos Therapeutics has announced that it has received FDA 510(k) clearance to market its innovative sleep apnea treatment solutions aimed at addressing moderate to severe obstructive sleep apnea (OSA) in children. This pivotal regulatory approval not only marks a significant achievement for the company but also positions it to disrupt the existing landscape of pediatric OSA treatments, which has long been a pressing health concern affecting countless children and their families across the United States. Understanding Pediatric Obstructive Sleep ApneaObstructive sleep apnea is recognized as a serious disorder characterized by repeated interruptions in breathing d...
January 8, 2024
In a groundbreaking development, Vivos Therapeutics has achieved a significant milestone with the issuance of a FDA 510(k) clearance for its CARE oral medical devices designed to treat severe Obstructive Sleep Apnea (OSA). This achievement marks a paradigm shift in the field of sleep medicine, as Vivos Therapeutics has successfully paved the way for a non-invasive and highly effective treatment option for individuals suffering from this debilitating condition.Obstructive Sleep Apnea, a chronic disorder characterized by repeated episodes of breathing cessation during sleep, affects millions worldwide and has long posed a challenge in terms of treatment efficacy. However, Vivos Therapeutics proprietary CARE o...
Vivos Therapeutics, a leading provider of oral appliances for treating sleep apnea, has recently signed an exclusive nationwide distribution agreement with Lincare. This strategic partnership aims to expand the reach of Vivos innovative oral appliances, ensuring that more individuals suffering from sleep apnea can receive effective treatment. Additionally, the company reported a revenue decrease in the second quarter of 2023 compared to its competitors. Let s examine the significance of these developments and their impact on Vivos Therapeutics. Nationwide Distribution Agreement with Lincare: Vivos Therapeutics has reached a significant milestone with the signing of an exclusive nationwide ...
Huntsman Corporation operates as a global manufacturer and marketer of differentiated chemicals. The company focuses on producing and selling a wide range of chemical products across various industries, including chemicals for plastics, coatings, textiles, detergents, and automotive markets. Huntsman's business model aims to meet customer needs through innovation, efficiency, and global distribution channels.
Koninklijke Philips Nv operates as a diversified technology company, focusing on areas such as healthcare, consumer lifestyle, and lighting. The company provides a wide range of products and solutions, including medical imaging equipment, home appliances, personal care products, and lighting solutions. Philips Nv's business model involves innovation-driven research and development, strategic partnerships, and a global distribution network to deliver its products and services to customers worldwide.
Vivos Inc operates as a biotechnology company that focuses on developing and commercializing products for regenerative medicine and drug discovery. Their business model revolves around the research, development, and sale of innovative therapies and diagnostics targeting various medical conditions.
ResMed Inc is a medical equipment company focused on creating and manufacturing products for the treatment of sleep apnea and other respiratory conditions. Their business model includes a combination of direct sales and partnerships with healthcare providers, ensuring wide distribution of their devices to patients worldwide. By leveraging advanced technology and data-driven solutions, ResMed aims to enhance patient care and improve health outcomes for individuals with sleep-related breathing issues.
Sleep Number Corporation operates as a manufacturer and retailer of smart beds and sleep solutions. The company's business model revolves around offering personalized sleep experiences through its adjustable smart beds, designed to provide individualized comfort and improve sleep quality. With a combination of innovative technology, data-driven insights, and direct-to-consumer sales channels, Sleep Number aims to enhance customers' sleep health while providing a unique and tailored sleeping experience.
Sources:
Vivos Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Vivos Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
